Ubs Group Ag Enveric Biosciences, Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$8.8 - $16.2 $857,357 - $1.58 Million	-97,427 Reduced 99.51%	477 $0
Q1 2022 May 16, 2022	BUY	$12.5 - $52.0 $1.05 Million - $4.36 Million	83,938 Added 601.02%	97,904 $32,000
Q4 2021 Feb 14, 2022	BUY	$46.5 - $104.0 $627,238 - $1.4 Million	13,489 Added 2827.88%	13,966 $13,000
Q3 2021 Nov 15, 2021	SELL	$80.5 - $175.0 $5.39 Million - $11.7 Million	-66,919 Reduced 99.29%	477 $1,000
Q2 2021 Aug 13, 2021	BUY	$95.0 - $156.5 $3.41 Million - $5.62 Million	35,924 Added 114.15%	67,396 $160,000
Q1 2021 May 12, 2021	BUY	$131.5 - $245.0 $4.14 Million - $7.71 Million	31,472 New	31,472 $97,000

Ticker ENVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,078,270
Market Cap $1.04M
Description
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.